In 2016, FAIRR initiated a three-year collaborative engagement to ask large food companies to end the nontherapeutic use of antibiotics important to human health…
The latest update to this engagement outlines not only how investors are stepping up their efforts to manage these risks but also, what progress has been made on the issue from both the corporate and policy communities.
The use of antibiotics in protein supply chains is a leading cause of rising antimicrobial resistance (AMR) in humans. Globally, the food industry is the largest consumer of antibiotics and often uses medicines to prevent disease or promote growth in otherwise healthy farm animals.
In a recent report showing that drug-resistant infections could cost the world around US$100 trillion in lost output by 2050, the UK government described the practice as “excessive and inappropriate”.
The misuse of antibiotics presents a systemic risk to investor portfolios and public health, and this has relevance to the food, pharmaceutical, healthcare and insurance industries.
See all the briefings that the FAIRR Initiative has released on the overuse of antibiotics in protein supply chains.
The FAIRR Initiative publishes company-level analysis, which is exclusively available to our Investor Members.
The latest update was released in May 2019.